Skip to main content

Table 5 Mean per-patient costs (US$) by type of treatment initiated following first-line therapy (n = 82 with complete RU data)

From: The economic burden of advanced gastric cancer in Taiwan

Type of costs Costs during follow-up Annual costsa
BSC
(n = 20)
2nd-line TX
(n = 62)
BSC
(n = 20)
2nd-line TX
(n = 62)
Mean follow-up days (SD) 401 (251)
[Median: 305]
458 (334)
[Median: 338]
Direct medical costs, mean(SD) 24,911 (11,661) 25,938 (17,279) 27,583 (15,051) 26,059 (15,512)
 Inpatient costs 8386 (13,127) 7741 (8913) 8119 (11,093) 7393 (7835)
 Outpatient costs 3074 (2715) 3116 (2078) 3340 (2508) 3049 (1752)
 Chemotherapy related costs 13,451 (6223) 15,081 (13,174) 16,124 (10,140) 15,617 (11,291)
   - Drug costs 9240 (5184) 10,570 (11,974) 11,205 (7665) 10,817 (9975)
   - Drug administration costs 3355 (3017) 3524 (2520) 4045 (4224) 3907 (2874)
   - Costs of routine examinations 856 (537) 987 (669) 874 (311) 892 (299)
Direct non-medical costs, mean(SD) 4232 (2227) 4476 (2655) 4815 (2813) 4622 (2362)
 Transportation costs 629 (401) 678 (461) 718 (432) 698 (354)
 Caregiver costs 3602 (1925) 3798 (2250) 4098 (2435) 3925 (2057)
Morbidity costs 5325 (2824) 5531 (3276) 6042 (3538) 5666 (2905)
  1. Abbreviations: AGC Advanced Gastric Cancer, BSC Best Supportive Care, RU Resource Utilisation, SD Standard Deviation, TX Treatment
  2. Note: both parametric and non-parametric tests showed no statistically significant differences in per-patient costs (in terms of both follow-up and annual costs) between patients with BSC and patients with second-line treatment following first-line treatment
  3. aDifferent follow-up periods were adjusted for to estimate “annual” costs